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Hypersensitivity syndrome reactions (HSR) to antiepileptic drugs (AED) are associated with 
severe clinical cutaneous adverse reactions (SCAR). 
We aimed: to assess HSRs to AEDs using the in vitro lymphocyte toxicity assay (LTA) in patients 
who manifested HSRs clinically, to correlate LTA results with the clinical syndrome, to correlate 
LTA results with the human leukocyte antigen (HLA) allele B*1502 (HLA-B*1502) positivity in a 
Han Chinese-Canadian population, and to determine the cytokine network in this population.  
HSR patients developed fever and cutaneous eruptions in the presence or absence of organ 
involvement within 8 weeks of exposure to carbamazepine (CBZ), phenytoin (PHY) or lamotrigine 
(LTG). Control patients received AEDs without presenting HSR. We investigated 10 CBZ-HSR (4 
presented with Stevens-Johnson syndrome (SJS)), 24 CBZ-controls, 10 PHY-HSR (4 presented with 
drug-induced liver injury (DILI)), 24 PHY-controls, 6 LTG-HSR (1 SJS and 1 DILI) and 24 LTG-
controls. There were 30 Han Chinese individuals (14 HSR patients and 16 controls) in our cohort. 
LTA toxicity greater than 12.5%±2.5% was considered positive. Differences among groups were 
determined by analysis of variance. In addition, we measured cytokine secretion in the patient 
sera between 1 month and 3 years after the event. All Han Chinese individuals and 30% of 
Caucasians were genotyped for HLA-B*1502. 
A perfect correlation (r=0.92) was observed between positive LTA and clinical diagnosis of DILI 
and SJS/toxic epidermal necrolysis (TEN). HLA-B*1502 positivity in Han Chinese is a predictor of 
CBZ-HSR and PHY-HSR. HLA-B*1502-negative Han Chinese receiving only CBZ or a combination of 
CBZ-PHY tolerated the drug(s) clinically, presenting negative CBZ-LTA and PHY-LTA. However, 3 
patients presenting negative CBZ-LTA and PHY-LTA, as well as negative HLA-B*1502, showed 
positive LTG-LTA (38%, 28% and 25%, respectively), implying that they should not be prescribed 
LTG. Three patients had LTA positive to both PHY and CBZ, and 3 others had LTA positive to both 
PHY and LTG. Clinically, all six patients presented HSR to both drugs that they tested positive to 
(cross-reactivity). Patients were grouped based on the clinical presentation of their symptoms as 
only rash and fever or a triad that characterizes “true” HSR (rash, fever and DILI or SJS/TEN). 
Levels of pro-inflammatory cytokines were significantly higher in patient sera compared to 
control sera. More specifically, the highest levels of tumor necrosis factor (TNF)-α was measured 
in patients presenting “true” HSR, as were the apoptotic markers Fas, caspase 8 activity and M30.  
We concluded that he LTA is sensitive for DILI and SJS/TEN regardless of drug or ethnicity. HSR 
prediction will prevent AED-induced morbidity. In Han Chinese, HLA-B*1502 positivity is a 
predictor for CBZ-HSR and PHY-HSR. Its negativity does not predict a negative LTG-HSR. There is 
cross-reactivity between AEDs. Additionally, T-cell cytokines and chemokines control the 
pathogenesis of SJS/TEN and DILI, contributing to apoptotic processes in the liver and in the skin. 
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Introduction 
Increasing knowledge about the mechanisms involved in the development of seizures, as well as 
improved understanding of the cellular effects of antiepileptic drugs (AED), have resulted in links 
between demonstrated molecular actions of these drugs and the types of seizures against which 
they are effective. A number of AEDs have been synthesized, with the goal of adapting synaptic 
function in order to regulate seizure frequency or occurrence. “First generation” AEDs include 
carbamazepine (CBZ), phenytoin (PHY), phenobarbital and valporate, whereas felbamate, 
gabapentin, lamotrigine (LTG), topiramate, levitrcetam, oxcarbazepine (ox-CBZ) and zonisamide 
are classified as “second generation” AEDs. Aromatic AEDs include CBZ, PHY and phenobarbital.1 
CBZ and PHY are structurally related to one another, while LTG is not. PHY is para-hydroxylated 
by cytochrome p450s primarily to two enantiomers, and further metabolized to a catechol that 
spontaneously oxidizes to semiquinone and quinine species.2-4 Major CBZ metabolism pathways 
include oxidation, hydration to 2- and 3-hydroxy-CBZ, which can be further oxidized to a catechol 
or an iminoquinone.5,6 LTG is largely metabolized in the liver by glucuronic acid conjugation, 
producing a 2-N-glucuronide conjugate, which can be hydrolyzed to beta-glucuronidase.7   
Interactions between AEDs are important in examining drug function and metabolism. CBZ and 
PHY decrease the half-life of LTG in the body, while valporate increases it.8 
Hypersensitivity reactions (HSR) are a common feature of anticonvulsants, being noted in 30% 
and 70% of patients with drug-induced liver injury (DILI) caused by CBZ and PHY, respectively.9,10 
To establish whether a drug is the cause of an immune-mediated reaction, alternative causes, 
latency of a reaction after drug intake, improvement after drug cessation, previous patient cases, 
and rechallenge have to be examined.9  
CBZ, PHY and LTG have been associated with HSRs. LTG was reported to produce Stevens-
Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and DILI.11-13 Most HSR cases occur 
during the first eight weeks of treatment.14-17 HSRs refer to dose-independent, idiosyncratic, 
severe adverse drug reactions (ADR).18,19 Clinically, a triad of fever, rash and organ manifestation 
defines a “true” HSR.9,18,20,21  
Skin manifestations include exanthematous rash, blistering eruptions such as erythema 
multiforme, SJS and TEN.16,22-25 SJS and TEN are severe cutaneous adverse reactions (SCAR).26-34 
Epidermal detachment below 10% is defined as SJS, whereas it is considered TEN above 30% 
[35,36]. Epidermal detachment between 10% and 30% defines transitional SJS/TEN.37,38 The 
incidence of TEN is estimated between 1-2 cases/million people/year, with a mortality rate of 
30%, whereas there are 2-7 cases/million people/year of SJS, with a mortality rate of 1-3%.39,41 
AEDs are among the leading causes of SCAR,42-44 drug-induced hypersensitivity syndrome 
(DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS)42,45,46 and DILI.47 Interestingly, 
while AEDs were the second leading cause of cutaneous ADRs, CBZ (10.3%) and PHY (9.6%) were 
the AEDs most often implicated, with CBZ the primary cause of SJS/TEN (24.0%) in Malaysia.48  
Genetic markers such as the human leukocyte antigen (HLA) are useful in predicting an 
individual’s predisposition AED-HSR. Ever since it was first linked with CBZ-SJS in Han Chinese,49 
HLA allele B*1502 (HLA-B*1502) has become the strongest HLA correlation among human 
diseases (98% negative predictive value, 92% sensitivity and 4.2%-19% false positivity).50 This 
association holds true for certain ethnic groups only, in particular Han Chinese, Thai, Malay and 
to a lesser degree, Indians.50,51  
HSR cases accompanied by hepatocytotoxicity are fewer than HSR cases with dermatologic 
presentations. DILI may lead to liver failure and transplant.10,25  
Regardless of ethnicity, HSR predisposition can be predicted by the in vitro lymphocyte toxicity 
assay (LTA).52,53 The mitochondrial enzyme succinate dehydrogenase-based LTA was validated 
versus clinical manifestations.53 Neuman et al.53also validated the new colorimetric methodology 
versus the previous LTA based on trypan blue uptake measured by microscopic counting of 
cells.52 Reactive metabolites of drugs are generated using murine hepatic microsomes as a 
source of cytochrome p450s.16,53,54 The LTA is based on the hypothesis that human lymphocytes 
in vitro mimic functional cells in vivo. Human lymphocytes from patients with a suspected HSR 
are used as surrogate target cells for safe in vitro rechallenge. Lymphocytes are suitable as they 
possess the patient’s phenotype. They also contain detoxification enzymes such as epoxide 
hydroxylases and glutathione S transferases, while expressing phenotypic individual variability in 
these enzymes. The LTA was validated for AEDs such as CBZ, PHY, valproic acid, zonisomide and 
Phenobarbital.25,53 
The HSR is a complex clinical manifestation, whose diagnosis rests mainly on clinical data. We 
demonstrated that predisposed individuals have lymphocytes that show cytotoxicity when 
exposed to the incriminated drug in vitro. The LTA remains a diagnostic tool applied successfully 
in AED-HSR in individuals with different ethnic backgrounds, which has never been directly 
compared to results of HLA genotyping. 
Oxidative cell damage caused by the generation of reactive drug species may also cause or 
contribute to the release of cytokines that warn the immune system of cellular stress and 
damage.16,55,56 Several signals may occur in a variety of settings, including infection and surgery, 
where they promote an immune response to eliminate these potentially dangerous calls.57 T-cell-
dependent immune responses encompass the type 1 T-helper response (Th1) associated with 
regulation of cell-mediated immune responses, or the type 2 T-helper response (Th2) which 
plays an important role in antibody or humoral immune responses.57 Cytokines play a role in the 
immuno-pathological and molecular mechanisms of drug-induced HSR.55 Alteration in the 
balance of Th1 cytokines, such as interleukins (IL) (IL-1, IL-2, IL-6, IL-18) and tumor necrosis 
factor (TNF)-α, and Th2 cytokines (IL-4, IL-10) are important factors in HSR. Pro-inflammatory 
cytokines and chemokines act as signals for antigen-presenting cells, leading to necrosis, 
apoptosis and organ damage.16  
This study aimed to: 1-assess AED-HSRs using the in vitro LTA in the ethnically-diverse Canadian 
population who manifested HSRs, including Han Chinese; 2-correlate LTA results to clinical 
symptoms; 3-correlate LTA results to HLA-B*1502 in Han Chinese-Canadians; and 4-determine 
the cytokine network.  
 
Patients and Methods 
PATIENTS 
Patients with clinical HSR manifestation [rash, fever and organ (skin, liver) involvement] within 8 
weeks of exposure to AEDs (CBZ, PHY and LTG) belonging to an epilepsy clinic (PH) or referred to 
a liver consult (LC) were included into the study. Experts have made the clinical diagnosis of type 
of seizure (PH), DILI (LC) and dermatological involvement (burn unit surgeons and dermatologist 
from the referral hospitals). Controls consisted of patients with epilepsy receiving AEDs without 
developing HSRs. The laboratory was blinded for clinical phenotypes of the participants.  
We studied: 10 PHY-HSR (4 DILI), 24 PHY-controls, 10 CBZ-HSR (4 SJS), 24 CBZ-controls, 6 LTG-HSR 
(1 SJS and 1 DILI) and 24 LTG-controls. LTA toxicity higher than 12.5%±2.5% was considered 
positive.  
The median time latency (interquartile range) between start of drug intake and index-day was 
less than 3 weeks [CBZ: 12 days (8-16), PHY: 12 days (10-18) and LTG: 9 days (4-20)].  
There were 30 Han Chinese individuals (14 HSR patients and 16 controls). All Han Chinese 
individuals underwent HLA genotyping. The ethnical distribution of HSR patients and therapy-
tolerant controls was 50% Han Chinese, 40% Caucasians, 8% Hispanic and 2% African-Americans. 
The neurologist (PH) established the causality to a specific drug and the hepatologist (LC) was 
consulted for cases presenting liver involvement. The clinical biochemist and pharmacology 
specialist (MN) was responsible for the study design, the laboratory diagnosis and the technical 
procedures, as well as writing the paper with the toxicology specialist (RN). Ethical approval for 
the study was obtained from the Scientific and Ethics Review Committees of the North York 
General Hospital, Toronto, Canada. All patients signed the informed consent form before 
participating in the study. The LTA was performed 2-3 years after the HSR in patients presenting 
at the clinic with a non-active adverse event. A single blood sample was drawn from each patient, 
which was used to extract the lymphocytes for the LTA and to obtain the sera for the cytokine 
analysis. Anonymous clinical description was matched to each sample.  
CHEMICALS 
Chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Microsomes were 
obtained from mice induced to a certain cytochrome p450 as previously described.53 The 
microsomal solution was diluted in HEPES buffer. Gibco® (InVitrogen; Carlsbad, California, USA) 
is the manufacture of Dulbecco’s modified eagle medium (α-MEM). Generic drugs (CBZ, LTG) 
were manufactured by Apotex Inc. (North York, Ontario, Canada, 
http://www.apotex.com/ca/en/search.asp).  
PREPARATION OF THE LTA 
Samples belonging to both sensitive and tolerant patients were incubated in the presence or 
absence of the microsomal fraction as previously described.53 The parental drug was added at its 
therapeutic concentration.53 The HLA polymorphism was determined using the method 
described by Kazeem et al.58 
Enzyme-linked immunosorbent assay (ELISA) immunoassay kits for human IL-1, IL-2, IL-4, IL-5, IL-
6, IL-8, IL-10, MCP1, regulated upon activation normal T-cell expressed and secreted (RANTES) 
and TNF-α (e-Bioscience, San Diego, CA, USA), as well as Fas, cleaved caspase 8, M30-
Apoptosense ELISA (Bender MedSystems, Vienna, Austria) were used for quantitative 
determination. We used standards and reference reagents available from Bender MedSystems 
(Vienna, Austria). Each specimen was analyzed in triplicate with 95% sensitivity and 90% 
specificity.  
CALCULATIONS AND STATISTICS 
LTA toxicity higher than 12.5%±2.5% was considered positive. These cut-off toxicity values were 
previously validated.53 Results that do not exceed these parameters indicate a negative LTA. 
Differences among groups were determined by the use of confidence intervals (CI) and analysis 
of variance. The χ2 test or Fisher's exact test was used to compare frequency data between 
groups. The Wilcoxon rank sum test was used to compare differences between groups. Binomial 
logistic regression was used to calculate the degree of correlation and predictability of the 
variables (clinical drug exposure results) to the LTA. The method used to estimate the model was 
the forward stepwise (likelihood ratio) method. The Student’s 2-tailed t-test for independent 
samples was also performed against subgroups that were clinically tolerant or clinically 
hypersensitive within each drug treatment (CBZ, PHY and LTG) to illustrate whether toxicity 
results were distinct. Statistical analysis was performed using SPSS Version 12.0.1 (Chicago, 
Illinois, USA). We presented the results graphically using Microsoft Excel 2000 (Redmond, 
Washington, USA). Most of our patients took the therapeutics because of their chronic condition 
(i.e. epileptic seizures).  
We also took into consideration all the non-drug risk factors such as chronic diseases (e.g. cancer, 
trauma) that required chronic therapeutic interventions in addition to AEDs. Also, we noted 
existing radiotherapy, recent viral disease or chronic viral infection. 
 
Results 
All patients with clinical manifestations to AEDs presented positive LTA to the incriminating drug. 
Controls tolerant to the drug presented negative LTA to the respective drugs. Figure 1 presents a 
graphical illustration of the LTA values of all patients tested. Patients were grouped based on the 
clinically presentation of their symptoms as follows: only rush and fever or a triad that 
characterizes “true” HSR (rash, fever and DILI or SJS/TEN), and the controls (individuals tolerating 
the drug). Result are given as mean percentage of toxicity and standard deviation (SD) of toxicity 
for each drug.  
There were no statistically significant differences between the mean ages of sensitive versus 
clinically-tolerant patients (32.5±24.5 and 38.5±16.0) (p=0.256). The statistical analysis of 
patients with DILI or SJS/TEN indicated an LTA sensitivity of 92.9%. Patients presenting a marginal 
LTA clinically demonstrated rash and fever only. The negative predictive value was 98.9%. This 
suggests a strong true-positive rate. The specificity of the reaction was 99.1%, which nicely 
identifies patients without the disease. There were 3 patients who presented a positive LTA to 
CBZ and also illustrated a positive PHY-LTA. Also, 3 PHY-HSR patients showed a positive LTG-HSR. 
Clinically, these patients developed HSR with liver involvement after AED therapy.  
A 76 year-old Caucasian male demonstrated cross-reactivity to CBZ and PHY. This individual 
presented SJS with liver involvement after PHY-CBZ therapeutic doses. His laboratory data 
showed high alanine aminotransferase (ALT) and elevated aspartate aminotransferase (AST) and 
bilirubin x 3 versus the normal. Two young Han Chinese patients showed SJS clinically to both 
CBZ and PHY with extremely elevated LTA values (53% CBZ-LTA and 28% PHY-LTA, and 38% CBZ-
LTA and 26% PHY-LTA, respectively). The LTA for CBZ and PHY correlated with the clinical 
presentation and with HLA-B*1502 positivity. All 3 Han Chinese patients that had SJS also had 
positive HLA-B*1502. Our study confirms that CBZ-HSR can be predicted by the presence of HLA-
B*1502, while an HLA-B*1502-negative status is protective against CBZ sensitivity in Han Chinese 
patients. The LTA is predictive for both CBZ-HSR and PHY-HSR, and can be correlated with HLA-
B*1502 positive results in Han Chinese individuals. The high cytotoxicity confirms the predictive 
value of the LTA in this population.  
In the present work, we define the cytokine levels in the sera of controls tolerant to AED and HSR 
patients (Table 1). There is a clear partition between the levels of cytokines in controls, patients 
presenting only with rush, and patients presenting with the triad of rash, fever and organ 
involvement. Patients presenting with SJS/TEN and DILI show elevated levels of Fas and caspase 
8, pointing to the apoptotic processes involved in the immunopathogenesis of severe adverse 
events such as DILI and SJS/TEN. There is a statistical difference between the levels of cytokines 
in control individuals and patients presenting adverse reactions and between patients presenting 
only with rash and patients presenting with DILI or SJS/TEN (Table 1).   
 
Discussion 
It is crucial to have a complete understanding of the biochemical processes that occur during 
HSR since it would allow for a better comprehension of any predisposing factors, potential cross-
reactivity, and the required duration of treatment. Ultimately, this analysis would aid clinicians in 
their assessment and decisions regarding potential therapies or the possible switch of the 
present therapy to a more effective one. The LTA is an in vitro assay that allows assessment of 
potential HSRs to a drug metabolite. This test is based on mitochondria dysfunction and a lack of 
drug detoxification capabilities in people sensitive to certain drugs. Several surveillance 
strategies have evolved that limit mitochondrial damage and ensure cellular integrity. 
Intraorganellar proteases conduct protein quality control and exert regulatory functions, 
allowing mitochondria to protect against apoptosis. Cell death caused by the metabolite can be 
detected as mitochondrial damage upon exposure to reactive drug metabolites.53 Mitochondrial 
damage may only signify a fraction of the complications involved in HSR, but it is a critical one 
nonetheless. Defects in any of the five complexes in the respiratory chain would greatly add to 
mitochondrial toxicity.57 The LTA is a marker of one such disorder, as it highlights genetic 
deficiencies in succinate dehydrogenase, a specific enzyme part of complex II in the 
mitochondrial respiratory chain. Since succinate dehydrogenase is specific to mitochondrial 
activity, its dysfunction would indicate cell death when the cell is subjected to stress.53 We have 
already performed similar studies in individuals who presented HSR to AEDs.16,53 The present 
study confirms that the LTA can predict an HSR to AEDs in an ethnically-specific population of 
Han Chinese individuals living in Canada, an environment different from that which their 
“mainland” ancestors were exposed to. There is no overlap in the patients studied in the prior 
work and the patients studied in the present work. The present work validates the usefulness of 
this diagnostic and predictive assay to be utilized in possible HSR reaction to AEDs, mainly in 
individuals of Asian descent living in Canada, while the main population studied in our previous 
studies was Caucasian. In the current study, AED samples were segregated into tolerant and 
hypersensitive groups.  
Cross-reactivity to anticonvulsants was observed clinically for a number of decades between CBZ, 
PHY and valproic acid.33,59-64 In the present work, we observed cross-reactivity between LTG and 
CBZ. The phenomenon may be explained by the ability of T-cells to recognize the major 
histocompatibility complex (MHC) of a drug-MHC complex. We demonstrated that the LTA is able 
to indicate a possible clinical AEDs cross-reactivity.  
Early diagnosis of an HSR is important in improving the quality of life in patients. The high 
frequency of rashes and a lack of efficacy are the main reasons for medication substitution in 
anti-epilepsy therapy. To avoid possible HSRs, testing is strongly advised. The LTA allows 
neurologists a routine analysis to predict and prevent an adverse reaction. The test may 
eventually help elucidate the mechanism of cytotoxicity caused by reactive metabolites, and the 
patterns of inheritance of defects in detoxification pathways. 
Our group analyzed the composition of circulating cytokines and their cellular expression in 
lymphocytes, using markers of cell activation such as the Fas/Fas ligand system.16 Our results 
confirmed that the apoptotic pathway is significantly activated in SJS/TEN.55 Fujita et al. 
described the role of inflammatory cytokines IL-1 and IL-5, and chemokines CCL5, CCL17 and 
CXCL10 in cutaneous immune inflammation.65 In our previous work,55 we demonstrated the 
immunochemical presence of apoptosis and necrosis markers in the skin biopsy of a patient with 
TEN, as well as the clear distribution of pro-inflammatory cytokines in the sera of patients with 
ibuprofen-induced SJS/TEN.  
The present work confirms that an HSR is a clinical reaction with genetic (HLA) and immune 
(cytokines) markers significantly different in susceptible versus tolerant individuals. Also, levels 
of cytokines differ between patients presenting only rash and patients presenting the triad of 
rash, fever and organ involvement (Table 1). Patients presenting with SJS/TEN or DILI show 
elevated levels of Fas and caspase 8, pointing to the apoptotic processes involved in the 
immunopathogenesis of severe adverse events such as DILI and SJS/TEN (Table 1). Cytokines 
released by the inflammatory process have the potential to alter oxidative drug metabolism, 
thereby increasing the production and toxicity of reactive drug metabolites therefore leading to 
toxic events. Pro-inflammatory cytokines expressed as a result of T-cell activation may represent 
a danger signal for HSR, as demonstrated by our findings. However, excluding neutrophils, these 
cells are also antigen-presenting cells, and are thus capable of biotransformation, conjugation 
and immune cell stimulation. In the present work, there is a positive correlation between LTG-
DILI/SJS cases and the serum level of chemo-attractant substances such as chemokines (IL-8, 
RANTES and monocyte chemo-attractant protein). Similar results have been shown in our 
previous work.57 Pro-inflammatory cytokines such as IL-1α and TNF-α are molecules that 
stimulate the synthesis of acute-phase proteins.66 IL-18 is pro-inflammatory at a very early step 
in the immune response. IL-6 stimulates most acute-phase proteins, while IL-10 is a prototype 
anti-inflammatory cytokine that regulates B-cell function.16 Moreover, Fas was shown to be 
dysregulated in SJS/TEN.55,67 T-cell memory is responsible for the recognition of “stress” signals 
represented by the exposure of lymphocytes to the insulting drug. We demonstrated a clear link 
between genetic factors such as HLA and immune responses to a specific injury. The more severe 
the injury, the higher the level of inflammatory responses and apoptosis were. 
The present work also takes into consideration the possibility that patients that are prone to HSR 
may develop cross-reactivity due to a structural similarity between CBZ and PHY, but also to an 
agent with a different structure and chemical properties, LTG. For example, one Han Chinese 
individual presented an HSR to both CBZ and PHY. The drugs were substituted with 
phenobarbital, which was well tolerated. Due to clinically-insufficient efficacy of phenobarbital, 
the patient was prescribed LTG. After two weeks of LTG therapy, the patient presented with LTG-
HSR. This patient presented a highly-positive LTA to CBZ, PHY and LTG, but negative to 
phenobarbital. We have demonstrated that the LTA is a powerful tool that can predict an HSR 
and cross-reactivity to AEDs regardless of the patient’s ethnic background. Should an LTG-LTA 
have been performed prior to administering this agent, the LTG-HSR could have been avoided.  
Our results show that LTG sensitivity is not significantly correlated to the presence of HLA-
B*1502. One HLA-B*1502-negative Han Chinese patient with negative CBZ-LTA and without 
clinical CBZ-HSR was in concordance with the previous observations showing that a negative 
HLA-B*1502 status permits safe CBZ use in Han Chinese individuals.68 However, he presented a 
high LTG-LTA (38%), showing that he is sensitive to LTG and should not take it. The LTA can thus 
be used to prevent an HSR. Another Han Chinese patient developed clinical SJS after a therapy 
with oxy-CBZ, CBZ and PHY. The patient presented a positive HLA-B*1502. LTA-PHY was positive 
(20%) and LTA-CBZ was highly positive (53%). However, the same patient showed only 7% toxicity 
to LTG-LTA. Therefore, if the LTA would be performed before prescribing the drugs, the SJS could 
be avoided by administering the safe LTG. This rationale has an important clinical implication, 
demonstrating that HLA-B*1502 is not predictive of LTG-HSR, and will permit safe LTG 
administration. These cases represent a confirmation that a positive HLA-B*1502 is a predictor 
for CBZ-HSR and PHY-HSR in Han Chinese population, but not for LTG-HSR.  
Chung et al. found that HLA-B*1502 was present in 100% of CBZ-SJS patients, 3% of CBZ-tolerant 
patients, and 8.6% of the general population among Han Chinese in Taiwan.49 The presence of 
this allele was predictive in 93.6% of cases, while its absence had a negative-prediction value of 
100%.49 Similar findings emerged from other Han Chinese populations.68-71 A significant 
association between CBZ-SJS/TEN and HLA-B*1502 was also found in Thai,72,73 Malay74 and, to a 
lesser degree, Indian patients.75 In a European study, the only HLA-B*1502-positive CBZ-SJS 
patients were of East Asian descent.76 No association was found in Japanese, Korean or 
Caucasian individuals. HLA-A*3101 was recently associated with CBZ-HSR, CBZ-maculopapular 
exanthema and CBZ-SJS/TEN in North European Caucasians,77 while HLA-B*1511 is associated 
with CBZ-SJS/TEN,78 and HLA-A*3101 with CBZ-cutaneous ADRs in Japanese.79  
HLA-B*1502 was associated with CBZ-induced SJS/TEN, but not with CBZ-induced mild 
maculopapular eruptions in central China.80 HLA-B*1502 was a risk factor for ox-CBZ-induced 
mild maculopapular eruptions,81 ox-CBZ- SJS/TEN and PHY-SJS/TEN.68 PHY-HSR was further 
associated with of HLA-B*1301, Cw*0801 and HLA-DRB1*1602 in a Chinese population.68 
The high incidence of HLA-B*1502 among Asian individuals (10-15%) correlates with a high 
incidence of SJS/TEN in this population (17 to 25 in every 10000 individuals in Taiwan and 
Thailand), compared to its low incidence among Caucasians (1% to 2%), which correlates with a 
low incidence in this population (1 to 6 in every 10000 individuals).49,50,82  
No association was found between LTG-SJS/TEN and HLA-B*1502 in Chinese,68 or European 
patients.58 In our study, we observed that negative HLA-B*1502 does not predict negative LTG-
HSR. We conclude that HLA-B*1502-negative status is not protective against LTG-HSR. For HLA-
B*1502-negative patients wishing to take LTG, an LTA is highly advised in order to ensure 
tolerance towards this anticonvulsant. The main limitation of our study is the relatively small 
number of Han Chinese patients presenting AED-HSR who participated in the study. 
 
Conclusion  
Current results demonstrate that the LTA is a good predictor tool for possible HSRs in individuals 
with epilepsy. HLA-B*1502 positivity represent a biomarker for possible CBZ-HSR and PHY-HSR in 
specific Asian populations, especially Han Chinese. More importantly, this work shows for the 
first time that HLA-B*1502 negativity does not prevent LTG-HSR in Han Chinese. The study also 
reinforces that immune mediated components, such as T-cells and their cytokines and 
chemokines products, can exacerbate cellular responses and create complex pathways that lead 
to cell apoptosis and consequently to a variety of clinical manifestations. Additionally, it has been 
confirmed that the LTA is a valuable method for predicting and confirming HSR to a specific drug. 
We have proposed that the LTA could be used as a screen tool for those considering taking or 
changing AEDs, as means to avoid an HSR. Our study emphasizes the necessity to wisely monitor 
the patients clinically and by laboratory investigations when prescribing AEDs, in order to 
avoiding AED-HSRs. Personalized medicine and assessing individual risk to adverse drug reaction 
is important for physicians and patients, since alternatives for the drugs involved may be needed 
for future safe treatment.  
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Table 1 
Cytokines  
(mean ± SD) 
Control 
24 x 3 = 72 
Patients 10 PHY + 10 CBZ + 6 LTG = 26 
Rash + Fever 6 PHY + 6 
CBZ + 4 LTG = 16 
SJS/TEN (4 CBZ + 1 
LTG) + DILI (4 PHY + 
1 LTG) = 10 
Cytokines  
(mean ± SD) 
Control 
24 x 3 = 72 
Patients 10 PHY + 10 CBZ + 6 LTG = 26 
Rash + Fever 6 PHY + 6 
CBZ + 4 LTG = 16 
SJS/TEN (4 CBZ + 1 
LTG) + DILI (4 PHY + 
1 LTG) = 10 
IL-1 pg/mL 45±15 60±25 220±20^ 
IL-2 pg/mL 35±15 70±15 260±10^ 
IL-4 pg/mL 64±10 46±14 22±4# 
IL-5 pg/mL 25±15 166±16* 350±15^ 
IL-6 pg/mL 38±10 36±10 49±6 
IL-8 pg/mL 69±10 108±15 195±15^ 
IL-10 pg/mL 30±5 40±12 65±25 
MCP 1 pg/mL 30±2.5 36±4 320±22^ 
RANTES pg/mL 50±20 105±15* 150±15^ 
TNF-α pg/mL 50±10 130±15* 170±10^ 
Fas ng/mL 2.0±1.0 12±4* 20.0±5.0^ 
M30 (%) 18±5 28±15 40.0±10.0^ 
Caspase 8 IU/mL 5.0±1.0 18±8 25.0±15.0^ 
Caspase 3 IU/mL 4.0±1.0 18±12 35.0±10.0^ 
 ^p<0.001 higher vs. control 
*p<0.05 higher vs. control 
#p<0.05 lower vs. control 
Figure 1 LTA values for all patients  
Patients were grouped based on the clinically presentation of their symptoms as controls 
tolerating the drug (white), HSR patients presenting only rash and fever (grey) or patients 
presenting a triad of rash, fever and SJS/TEN or DILI that characterizes “true” HSR (black). The 
LTA value is given as mean percentage of toxicity and standard deviation (SD) in lymphocyte 
toxicity for each drug.  

